Brain scans can reveal a surprising amount about dementia, from the physical shrinking of memory-critical structures to the buildup of toxic proteins years before symptoms become obvious. No single scan gives the full picture, but different imaging techniques each expose a distinct layer of the disease. Structural MRI shows tissue loss and vascular damage, PET scans light up abnormal protein deposits and metabolic slowdowns, and newer methods track inflammation and blood flow changes. Together, these images have transformed dementia from something diagnosed mainly by clinical observation into a condition that can be seen, staged, and, increasingly, monitored during treatment.
The First Scan Most People Get
When someone shows up with memory problems or confusion, the initial brain scan is usually a CT or MRI, and its first job is not to confirm dementia. It is to rule out other explanations. Tumors, blood clots, fluid buildup in the brain, and other structural problems can mimic cognitive decline and are sometimes treatable. Clinical guidelines recommend that all patients presenting with dementia symptoms get structural imaging for exactly this reason.1PubMed Central. Reversible dementias CT is less sensitive than MRI for picking up subtle changes tied to cognitive impairment, but it remains a useful first-line tool for catching those secondary, sometimes reversible causes.2International Psychogeriatrics. The use of CT in dementia
If CT or MRI clears the deck of treatable causes, the same images then offer clues about the dementia itself. A radiologist looks for patterns of tissue loss, changes in white matter, old strokes, or tiny bleeds. Those patterns can narrow the field considerably, pointing toward one type of dementia versus another, even before more specialized scans enter the picture.
Structural MRI and Hippocampal Shrinkage
The hippocampus, a small curved structure deep in the brain, is essential for forming new memories and is one of the earliest regions to shrink in Alzheimer’s disease. MRI can measure this shrinkage with enough precision that hippocampal volume has become a widely studied marker of disease progression. A synthesis of evidence across 30 observational studies involving over 13,000 people found clear correlations between hippocampal volume and cognition, both at a single time point and over the course of a year or more.3SpringerOpen / CNS Drugs. Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease – Section: Analyses of HV–Cognitive Relationship in Anti-amyloid Interventional Trials In plain terms, a smaller hippocampus correlated with worse thinking skills, and faster shrinkage tracked with faster cognitive decline.
This relationship matters for treatment trials too. Across anti-amyloid drug trials involving roughly 10,000 participants, the degree to which a drug slowed hippocampal shrinkage lined up with how much it slowed cognitive decline.3SpringerOpen / CNS Drugs. Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease – Section: Analyses of HV–Cognitive Relationship in Anti-amyloid Interventional Trials That makes hippocampal volume on MRI one of the more practical yardsticks for judging whether a new drug is doing its job.
Beyond the hippocampus, structural MRI captures broader patterns of cortical thinning. In Alzheimer’s, the temporal and parietal lobes tend to waste away first. In frontotemporal dementia, the damage concentrates in the frontal lobes and the front portions of the temporal lobes. These regional signatures help clinicians tell one dementia subtype from another on the same scan.
How Different Dementias Light Up on FDG-PET
While MRI shows structure, FDG-PET shows function. This type of scan uses a radioactive glucose tracer to map which parts of the brain are burning through energy and which have gone quiet. Because neurons consume glucose when they are active, a region that shows low glucose uptake is essentially a region that has stopped working properly. Each dementia subtype produces a distinctive pattern of these metabolic “cold spots,” and clinicians use those patterns to make early and reasonably accurate diagnoses.4PubMed. Brain FDG PET and the diagnosis of dementia
In Alzheimer’s disease, the areas with reduced metabolism tend to cluster in the posterior cingulate gyrus, the precuneus, and the parietal and temporal association cortices. These are regions involved in memory consolidation and spatial orientation. Lewy body dementia produces a different map: glucose metabolism drops in the occipital cortex, the brain’s visual processing center, which helps explain why people with this condition often experience vivid visual hallucinations. Frontotemporal dementia, meanwhile, shows decreased metabolism predominantly in the frontal and anterior temporal regions, consistent with the personality changes and language difficulties that characterize it.5PubMed Central. PET approaches for diagnosis of dementia
Amyloid PET and Seeing the Plaques
One of the defining features of Alzheimer’s disease is the accumulation of amyloid-beta plaques between brain cells. For decades, the only way to confirm these plaques existed was through autopsy. Amyloid PET changed that by allowing doctors and researchers to visualize amyloid deposits in living patients.6PubMed Central. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
The accuracy of these scans has been validated against autopsy findings. In a phase 3 study of the tracer florbetaben, the scan correctly identified amyloid-positive cases with a sensitivity of about 98% and correctly identified amyloid-negative cases with a specificity of about 89%.7PubMed. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study A separate autopsy-validation study of florbetapir, another tracer, found sensitivity of 92% and specificity of 100% for detecting moderate-to-frequent plaques when the scan was done within two years of death, with the PET signal correlating strongly with actual amyloid burden measured at autopsy.8The Lancet Neurology. The Lancet Neurology
An amyloid-positive scan does not by itself mean a person has Alzheimer’s. Some cognitively normal older adults carry amyloid plaques for years before symptoms appear, and some never develop clinical dementia at all. But in someone already experiencing cognitive symptoms, a positive amyloid PET strongly supports an Alzheimer’s diagnosis. A negative scan, meanwhile, makes Alzheimer’s much less likely and pushes clinicians to consider other explanations.
Tau PET and Staging the Disease
Amyloid plaques are part of the Alzheimer’s story, but the other key protein, tau, is more closely linked to the actual damage neurons suffer. Tau tangles spread through the brain in a characteristic sequence, starting in the entorhinal cortex (near the hippocampus) and gradually invading wider cortical regions. Tau PET scans can map this progression in living patients.
Research using tau PET has confirmed the staging pattern that was originally described from autopsies. Cognitive decline first becomes measurable when tau concentrations rise in the entorhinal region, and it accelerates as tau spreads outward through the temporal and then the broader cortex.9Translational Psychiatry. Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study Early stages show isolated memory deficits, while later stages bring broader cognitive impairment and worse overall clinical ratings.10Journal of Nuclear Medicine. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
Tau PET remains mostly a research tool rather than a routine clinical test, but it shows accurate differentiation between Alzheimer’s patients and healthy controls and has a close relationship with clinical symptoms.11JAMA Neurology. Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment Its value lies in telling clinicians not just whether Alzheimer’s pathology is present but how far it has progressed, which has direct implications for prognosis and treatment planning.
Vascular Dementia on MRI
Not all dementia traces back to protein deposits. Vascular dementia, the second most common type, results from impaired blood flow to the brain. MRI is the primary tool for spotting the damage. The characteristic findings include white matter hyperintensities (bright patches on certain MRI sequences), lacunar infarcts (small strokes deep in the brain), and microbleeds. These white matter changes are thought to result from chronic low-grade oxygen deprivation in the brain’s deep white matter, driven by conditions such as high blood pressure and diabetes.12PubMed Central. Inflammation and white matter damage in vascular cognitive impairment
Stronger MRI magnets reveal more of this damage. At 7 Tesla, a field strength used mainly in research, nearly twice as many microbleeds were detected compared to standard clinical 1.5 Tesla MRI.13PubMed. 7 tesla MRI of microbleeds and white matter lesions as seen in vascular dementia That matters because microbleed counts can influence treatment decisions, especially when blood-thinning medications are being considered. The concern is real: what a standard-strength scanner misses, a higher-resolution scanner reveals, and the clinical picture can change accordingly.
Frontotemporal Dementia and Lewy Body Dementia
Frontotemporal dementia (FTD) is often misdiagnosed early on because it typically starts with personality and behavioral changes rather than memory loss. On MRI, FTD shows atrophy concentrated in the ventromedial frontal cortex, the posterior orbital frontal regions, and the insula bilaterally. The behavioral variant of FTD also affects the right dorsolateral frontal cortex, while semantic dementia (a language-dominant variant) produces striking tissue loss in the anterior temporal lobes and the amygdala bilaterally.14PubMed. Patterns of brain atrophy in frontotemporal dementia and semantic dementia These distinct atrophy maps help radiologists distinguish FTD subtypes from each other and from Alzheimer’s.
Lewy body dementia, the third most common neurodegenerative dementia, presents its own imaging challenge. Structural MRI changes can overlap significantly with Alzheimer’s. A specialized nuclear medicine scan, DAT-SPECT, fills the diagnostic gap. This scan measures dopamine transporter activity in the basal ganglia, a structure involved in movement control. Reduced uptake reflects the loss of dopamine-producing neurons, a hallmark shared with Parkinson’s disease. In detecting Lewy body dementia specifically, DAT-SPECT has demonstrated a sensitivity of about 80% and specificity of about 92%.15PubMed Central. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions That high specificity means a positive result strongly supports the diagnosis, though some overlap with other parkinsonian conditions requires careful clinical interpretation.
Perfusion Imaging Without a Radioactive Tracer
Arterial spin labeling (ASL) MRI offers a way to measure blood flow in the brain without injecting a radioactive tracer. Instead, it magnetically labels the blood flowing into the brain and uses that signal as a natural contrast agent. This technique has shown that people with Alzheimer’s and those with mild cognitive impairment have reduced blood flow in the parietal lobe, the angular gyrus, the middle temporal areas, and the precuneus, mirroring the metabolic patterns seen on FDG-PET.16PubMed. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI
Because blood flow changes may appear early in the disease process, ASL is being explored as a potential screening tool. It is noninvasive, repeatable, and can be added to a standard MRI session, making it practical in a way that PET scans are not.17PubMed Central. Arterial Spin Labeling MRI in Alzheimer’s Disease: A Systematic Review of Cerebral Perfusion Biomarkers If future research confirms its reliability for early detection, it could help identify at-risk individuals during routine brain imaging.
Imaging Inflammation in the Brain
Neuroinflammation, driven largely by the brain’s immune cells called microglia, is increasingly recognized as a contributor to dementia rather than just a bystander. PET scans targeting a protein called TSPO can visualize this inflammation. Increased TSPO density has been found in brain tissue from patients with various neurodegenerative diseases, and it colocalizes with activated microglia.18PubMed Central. Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia Elevated TSPO PET signal shows up in brain regions that correspond to the specific disease being studied, suggesting that inflammation tracks with the pathology rather than appearing randomly.
The limitation is a practical one. A common genetic variation in the TSPO protein reduces how tightly the PET tracers bind, meaning that a sizable portion of the population gives a weaker signal regardless of their actual inflammation levels.19PubMed Central. Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders This genetic quirk has limited the clinical utility of current TSPO tracers, though next-generation ligands are under development.
Predicting Who Will Progress
One of the most pressing questions in dementia care is whether someone with mild cognitive impairment will go on to develop full-blown Alzheimer’s or remain stable. Brain imaging plays a growing role in making that prediction. People who later convert to Alzheimer’s tend to show a specific pattern at baseline: atrophy in the temporal lobe gray and white matter, the posterior cingulate, the precuneus, and the insula, along with abnormal spinal fluid biomarkers. When brain atrophy patterns are combined with cerebrospinal fluid measurements, prediction improves over either one alone.20Neurobiology of Aging. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
Combining different imaging types also helps. One study found that a model using amyloid PET features alone reached a balanced accuracy of about 84% for predicting conversion, while combining structural MRI with FDG-PET achieved about 78% accuracy, suggesting that the two scan types capture complementary information about disease risk.21PubMed Central. Predicting conversion from mild cognitive impairment to Alzheimer’s disease: a multimodal approach Even standard MRI biomarkers extracted from FLAIR sequences showed the ability to identify differences between people who would stay stable and those who would progress, with some markers flagging risk up to four years before conversion.22PubMed Central. Detecting conversion from mild cognitive impairment to Alzheimer’s disease using FLAIR MRI biomarkers
Monitoring Treatment Side Effects
The arrival of anti-amyloid antibody drugs has created a new and urgent role for brain imaging: monitoring for a side effect called amyloid-related imaging abnormalities, or ARIA. These abnormalities come in two forms: swelling in the brain tissue (ARIA-E, visible as bright areas on fluid-sensitive MRI sequences) and tiny hemorrhages or iron deposits (ARIA-H, visible as dark spots on susceptibility-weighted sequences). Most cases are mild and resolve after the drug is paused, but severe cases can be dangerous.
Current recommendations call for regular MRI monitoring using at minimum three specific sequences: T2-FLAIR to detect swelling, T2* gradient echo to catch microbleeds, and diffusion-weighted imaging to distinguish ARIA from strokes.23PubMed Central. Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease Treatment decisions hinge on what the scans show: mild asymptomatic ARIA may allow continued dosing with extra monitoring, moderate cases warrant dose suspension, and severe or recurrent episodes call for stopping treatment altogether.24PubMed Central. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics For patients on these drugs, MRI has gone from a diagnostic tool to an ongoing safety monitor.
The Challenge of Mixed Pathologies
The brain scans described above work best when a patient has one clean diagnosis. Reality is messier. Mixed dementia, most commonly a combination of Alzheimer’s pathology and vascular brain injury, is particularly frequent in older adults and presents a real diagnostic challenge.25PubMed Central. The pathophysiology of mixed Alzheimer’s disease and vascular dementia The cognitive profile in mixed cases tends to be dominated by the Alzheimer’s component, with severe memory loss and hippocampal atrophy, while the vascular contribution shows up as white matter hyperintensities, infarcts, and hemorrhages on structural MRI.26PubMed Central. Clinical and imaging features of mixed Alzheimer and vascular pathologies
Complicating matters further, very small vascular injuries called microinfarcts currently escape detection by standard clinical MRI, even though they may contribute meaningfully to cognitive decline. The diagnostic process for any dementia evaluation should consider these overlapping pathologies rather than trying to force a single label.27PubMed. Neuroimaging in Dementia: More than Typical Alzheimer Disease Describing the individual mix of neurodegenerative and vascular markers on a patient’s imaging gives a more honest and useful clinical picture than a binary diagnosis.
Imaging Versus Blood Tests
Blood-based biomarkers for Alzheimer’s have generated enormous excitement in recent years, and for good reason: a blood draw is cheaper, faster, and more accessible than a PET scan. But imaging and fluid biomarkers are not interchangeable. They measure different things. Imaging biomarkers directly show the extent and regional distribution of pathology in the brain, while blood and spinal fluid biomarkers capture dynamic, soluble signals of disease activity.28Journal of Nuclear Medicine. Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
This distinction matters practically. A blood test might tell a clinician that amyloid pathology is happening somewhere, but it cannot show where the damage is concentrated, how much tissue has already been lost, or whether the pattern matches Alzheimer’s versus another condition. An amyloid PET scan can. Conversely, a blood test can be repeated frequently and cheaply to track how rapidly pathology is changing, something that would be impractical with repeated PET scans. The emerging consensus is that the two approaches complement each other rather than compete, with blood tests likely serving as an initial screen and imaging stepping in when a detailed picture of brain pathology is needed.
Artificial Intelligence Reading Scans
Machine learning algorithms are increasingly being applied to dementia brain scans, and the results have been striking. Several studies have reported classification accuracies above 95% for distinguishing Alzheimer’s from mild cognitive impairment or normal cognition when feeding AI models the combined data from PET and MRI.29PubMed Central. Artificial Intelligence in Alzheimer’s Disease Diagnosis and Prognosis Using PET-MRI: A Narrative Review of High-Impact Literature Post-Tauvid Approval These numbers sound impressive, but context matters. Most of these results come from well-curated research datasets where patient groups are clearly defined. Performance in messier real-world clinical settings, where patients often have multiple overlapping conditions, is likely to be lower.
Still, AI’s ability to detect subtle patterns across thousands of brain scans at once is something no human radiologist can replicate. The technology’s most promising near-term role may be in flagging early changes that fall below the threshold of what a clinician would notice on visual inspection, giving patients and their families a longer window to plan.
Atypical Presentations That Change What Scans Show
Not every case of Alzheimer’s looks like the textbook description on imaging. Posterior cortical atrophy, sometimes called the “visual variant” of Alzheimer’s, affects the back of the brain rather than the hippocampus. Patients lose the ability to process visual information, struggling with reading, judging distances, or recognizing objects, even though their memory may be relatively preserved early on. On MRI, these patients show atrophy concentrated in the occipital, parietal, and posterior temporal lobes, more severe on the right side. Compared with typical Alzheimer’s patients, they show greater damage to the right visual association cortex but less hippocampal atrophy on the left.30PubMed Central. Imaging correlates of posterior cortical atrophy
This variant matters because it can be missed if a clinician or radiologist only looks for the classic Alzheimer’s pattern of hippocampal shrinkage. A scan that appears “not too bad” in the memory regions may hide devastating damage to the visual cortex. Awareness of atypical presentations is one reason modern dementia imaging tries to evaluate the whole brain rather than just checking a few expected hotspots.
The Psychological Weight of a Brain Scan Result
Brain scans carry emotional consequences beyond their diagnostic utility. Research suggests that a positive brain scan result — one showing Alzheimer’s-related pathology — increases confidence in the diagnosis among the people who learn about it, but also increases stigma. In a vignette-based experiment, participants shown a scenario involving a positive brain scan endorsed roughly three and a half times greater worries about structural discrimination compared to those shown a negative result. They also reported greater perceived symptom severity, more social distance, and stronger emotional reactions including both pity and antipathy.31The Journals of Gerontology: Series B. Double-Edged Sword: A Positive Brain Scan Result Heightens Confidence in an Alzheimer’s Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette-Based Experiment
This dual effect makes scan disclosure a genuinely complicated clinical decision. A clear positive result can help a patient and family understand what is happening, access appropriate care, and plan for the future. But it can also change how others perceive and treat them. The science of what brain scans can reveal is advancing rapidly. The harder, slower work of figuring out how to communicate those results in a way that helps more than it hurts is still catching up.